title: Peptide Receptor Radionuclide Therapy (PRRT) of Medullary and Nonmedullary Thyroid Cancer Using Radiolabeled Somatostatin Analogues.
abstract: As therapeutic options in advanced medullary and non-iodine avid differentiated (nonmedullary) thyroid cancers are limited and associated with significant toxicity, targeting of somatostatin receptors (SSTRs) for internal radiation therapy provides a promising option. Theranostics (therapy and diagnosis) using radiolabeled somatostatin analogues has proved to be a milestone in the management of SSTR-expressing tumors. Peptide receptor radionuclide therapy using (177)Lu-labeled or (90)Y-labeled somatostatin analogues may have a significant role in the management of medullary and nonmedullary thyroid cancers in those patients where PET/CT with (68)Ga-labeled somatostatin analogues demonstrates significant SSTR expression.
authors.affiliation: Department of Radiology, University of Pennsylvania, Philadelphia, PA; Department of Radiology, University of Minnesota, Minneapolis, MN.
authors.forename: Ali
authors.initials: A
authors.lastname: Salavati
authors.affiliation: Department of Nuclear Medicine, Bombay Hospital and MRC, Mumbai, India.
authors.forename: Ameya
authors.initials: A
authors.lastname: Puranik
authors.affiliation: THERANOSTICS Center for Molecular Radiotherapy and Molecular Imaging, ENETS Center of Excellence, Zentralklinik Bad Berka, Germany.
authors.forename: Harshad R
authors.initials: HR
authors.lastname: Kulkarni
authors.affiliation: Department of Nuclear Medicine, Mochtar Riady Comprehensive Cancer Centre-Siloam Hospitals, Jakarta, Indonesia.
authors.forename: Hendra
authors.initials: H
authors.lastname: Budiawan
authors.affiliation: THERANOSTICS Center for Molecular Radiotherapy and Molecular Imaging, ENETS Center of Excellence, Zentralklinik Bad Berka, Germany. Electronic address: richard.baum@zentralklinik.de.
authors.forename: Richard P
authors.initials: RP
authors.lastname: Baum
mesh_terms: D000818:Animals; D018278:Carcinoma, Neuroendocrine / Q000473:pathology / Q000532:radiotherapy*; D004351:Drug Resistance; D006801:Humans; D007553:Isotope Labeling; D017481:Receptors, Somatostatin / Q000378:metabolism*; D013004:Somatostatin / Q000031:analogs & derivatives* / Q000378:metabolism / Q000627:therapeutic use*; D013964:Thyroid Neoplasms / Q000473:pathology / Q000532:radiotherapy*
chemical_list: D017481:Receptors, Somatostatin; D013004:Somatostatin